Предпосылки и преимущества комбинированной терапии розувастатином и фенофибратом

V. S. Gurevich; M. V. Ezhov; I. V. Sergienko; A. S. Alieva; U. V. Chubykina; Yu. A. Prus; A. G. Obrezan; G. P. Arutyunov

doi:10.34687/2219-8202.JAD.2021.03.0003

Authors

V. S. Gurevich St Petersburg University, St Petersburg, Russia
M. V. Ezhov National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
I. V. Sergienko National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
A. S. Alieva Almazov National Medical Research Centre, St Petersburg, Russia
U. V. Chubykina National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
Yu. A. Prus National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
A. G. Obrezan St Petersburg University, St Petersburg, Russia
G. P. Arutyunov Pirogov Russian National Research Medical University, Moscow, Russia

DOI:

https://doi.org/10.34687/2219-8202.JAD.2021.03.0003

Abstract

The morbidity and mortality rates from cardiovascular diseases worldwide remain extremely high. Dyslipidemias play a central role among the risk factors involved in the pathogenesis of atherosclerosis and deserve targeted treatment. The guideline discusses combination lipid-lowering therapy aimed at reducing apoB-containing lipoproteins.